Cohen Investment Advisors LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Cohen Investment Advisors LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 11.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 21,699 shares of the company’s stock after buying an additional 2,169 shares during the period. Johnson & Johnson accounts for about 2.1% of Cohen Investment Advisors LLC’s portfolio, making the stock its 21st largest position. Cohen Investment Advisors LLC’s holdings in Johnson & Johnson were worth $3,599,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the company. MRP Capital Investments LLC increased its holdings in Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock valued at $237,000 after buying an additional 65 shares in the last quarter. Syverson Strege & Co grew its position in shares of Johnson & Johnson by 4.9% during the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock valued at $202,000 after acquiring an additional 65 shares during the period. Sage Mountain Advisors LLC raised its holdings in Johnson & Johnson by 0.5% in the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock worth $2,106,000 after purchasing an additional 67 shares during the period. MBA Advisors LLC boosted its position in Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after purchasing an additional 68 shares in the last quarter. Finally, Sovereign Financial Group Inc. grew its holdings in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after purchasing an additional 69 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.2%

Johnson & Johnson stock opened at $155.90 on Friday. The company has a market capitalization of $375.11 billion, a PE ratio of 17.34, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a 50 day moving average price of $153.68 and a 200 day moving average price of $154.09.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.34%. Johnson & Johnson’s dividend payout ratio is 57.84%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Leerink Partnrs downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Leerink Partners cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Finally, Morgan Stanley raised their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.